TUFM Gene

TUFM Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">tufm</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TUFM</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Tu Translation Elongation Factor, Mitochondrial</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>16p11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[7284](https://www.ncbi.nlm.nih.gov/gene/7284)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[609377](https://www.omim.org/entry/609377)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>[ENSG00000178952](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178952)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P49411](https://www.uniprot.org/uniprot/P49411)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Translation elongation factor, GTP-binding protein</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>EF-Tu, mtEF-Tu, EFTU</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>High</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class

TUFM Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">tufm</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TUFM</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Tu Translation Elongation Factor, Mitochondrial</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>16p11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[7284](https://www.ncbi.nlm.nih.gov/gene/7284)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[609377](https://www.omim.org/entry/609377)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>[ENSG00000178952](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178952)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P49411](https://www.uniprot.org/uniprot/P49411)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Translation elongation factor, GTP-binding protein</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>EF-Tu, mtEF-Tu, EFTU</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>High</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Mitochondrial ribosome</td>
<td>Binding</td>
</tr>
<tr>
<td class="label">Mitochondrial tRNAs</td>
<td>Ternary complex</td>
</tr>
<tr>
<td class="label">GTP</td>
<td>Binding</td>
</tr>
<tr>
<td class="label">TSFM (EF-Ts)</td>
<td>Co-factor</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/infection" style="color:#ef9a9a">Infection</a>, <a href="/wiki/traumatic-brain-injury" style="color:#ef9a9a">Traumatic Brain Injury</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">77 edges</a></td>
</tr>
</table>

Overview

TUFM (Tu Translation Elongation Factor, Mitochondrial) encodes the mitochondrial translation elongation factor Tu (EF-Tu), a essential protein for mitochondrial protein synthesis and oxidative phosphorylation [1]. TUFM is one of the most abundant mitochondrial proteins and plays a critical role in delivering aminoacyl-tRNAs to the mitochondrial ribosome during translation.[@w2025] This function is fundamental to the assembly of the respiratory chain complexes, and mutations in TUFM cause severe mitochondrial encephalomyopathies including [Leigh syndrome](/diseases/leigh-syndrome) and combined oxidative phosphorylation deficiencies [2].

The mitochondrial translation machinery is distinct from the cytosolic translation system, reflecting the bacterial origin of mitochondria. TUFM represents the mitochondrial version of the bacterial EF-Tu, which is the most abundant protein in bacteria. This evolutionary conservation underscores the fundamental importance of mitochondrial translation for cellular energy production and survival.[@x2026]

Gene Information

Protein Structure and Function

Domain Architecture

TUFM is a GTP-binding protein with multiple functional domains:

• N-terminal domain: Mitochondrial targeting sequence (cleaved after import)
• Domain 1 (GTPase domain): Binds and hydrolyzes GTP
• Domain 2 (Domain 2): Interacts with aminoacyl-tRNA
• Domain 3 (Domain 3): Stabilizes the complex
• C-terminal region: Interfaces with mitochondrial ribosome

The Translation Cycle

TUFM participates in the mitochondrial translation elongation cycle [3]:

This cycle repeats for each amino acid incorporated into the growing polypeptide chain.

GTPase Activity

The GTPase activity of TUFM is regulated by:

• Ribosomal binding: The ribosome stimulates GTP hydrolysis
• Aminoacyl-tRNA: The ternary complex formation
• Guanine nucleotide exchange factors: For GTP regeneration

Role in Mitochondrial Function

Oxidative Phosphorylation

TUFM is essential for OXPHOS [4]:

• Complex I (NADH dehydrogenase): Requires 7 mtDNA-encoded subunits
• Complex III (Cytochrome bc1): Requires 1 mtDNA-encoded subunit
• Complex IV (Cytochrome c oxidase): Requires 3 mtDNA-encoded subunits
• Complex V (ATP synthase): Requires 2 mtDNA-encoded subunits

Mitochondrial DNA Translation

The mitochondrial genetic system:

• Encodes 13 essential OXPHOS subunits
• Uses a specialized genetic code (AGA, AGG = Stop)
• Requires unique tRNA modifications
• Depends on TUFM for protein synthesis

Complex Assembly

TUFM contributes to OXPHOS assembly:

• Facilitates co-translational assembly of membrane proteins
• Coordinates assembly of multi-subunit complexes
• Prevents aggregation of hydrophobic subunits

Disease Associations

Mitochondrial Encephalomyopathy

Mutations in TUFM cause severe neurological disease [5]:

Clinical Features:

• Early-onset encephalopathy
• Developmental regression
• Seizures
• Ataxia
• Cardiomyopathy
• Elevated lactic acid

• Bilateral basal ganglia lesions
• White matter abnormalities
• Cerebral atrophy

• Progressive condition
• Often fatal in childhood
• Variable phenotype severity

Leigh Syndrome

TUFM is a known cause of [Leigh syndrome](/diseases/leigh-syndrome) [6]:

• Subacute necrotizing encephalomyelopathy
• Characteristic "double comma" lesions in brainstem
• Elevated lactate in CSF
• Variable age of onset

Cardiomyopathy

Cardiac involvement in TUFM deficiency [7]:

• Hypertrophic cardiomyopathy
• Dilated cardiomyopathy
• Cardiac conduction abnormalities
• Often fatal in infancy

Combined Oxidative Phosphorylation Deficiency

TUFM mutations cause [8]:

• Multiple OXPHOS complex deficiencies
• Severe metabolic crisis
• Multi-organ involvement
• Early mortality

Neurodegenerative Diseases

Parkinson's Disease

Emerging evidence links TUFM to [Parkinson's disease](/diseases/parkinsons-disease) [9]:

Genetic Studies:

• TUFM variants identified in PD patients
• Some variants may increase susceptibility
• GWAS signals near TUFM locus

• TUFM expression altered in PD substantia nigra
• Mitochondrial dysfunction in PD models
• Interaction with PINK1/Parkin pathway

• Impaired mitochondrial translation
• Respiratory chain deficiency
• Increased susceptibility to stress

Alzheimer's Disease

TUFM alterations in [Alzheimer's disease](/diseases/alzheimers-disease) [10]:

• Reduced TUFM expression in AD brain
• Correlates with cognitive decline
• May contribute to mitochondrial dysfunction
• Interaction with amyloid pathology

Amyotrophic Lateral Sclerosis

TUFM in [ALS](/diseases/amyotrophic-lateral-sclerosis) [11]:

• TUFM variants in ALS patients
• Mitochondrial dysfunction in motor neurons
• Energy metabolism deficits
• Possible therapeutic target

Huntington's Disease

TUFM involvement in [Huntington's disease](/dineses/huntingtons-disease):

• Altered expression in HD models
• Mitochondrial dysfunction
• Energy deficit in striatal neurons

Expression Pattern

Tissue Distribution

TUFM is expressed ubiquitously with highest levels in:

Subcellular Localization

TUFM is localized to:

• Mitochondrial matrix: Primary location
• Mitochondrial nucleoid: Associated with mtDNA
• Mitochondrial ribosome: Part of translation machinery

Cell-Type Specificity

In the brain:

• Neurons: High expression
• Astrocytes: Moderate expression
• Microglia: Lower expression
• Oligodendrocytes: Variable

Interaction Network

Mitochondrial Translation Machinery

TUFM interacts with:

OXPHOS Assembly

TUFM interfaces with:

• mtDNA-encoded proteins
• Mitochondrial ribosome biogenesis factors
• Assembly chaperones

Quality Control

TUFM and quality control:

• Monitoring of translation accuracy
• Degradation of misfolded proteins
• Ribosome recycling

Therapeutic Implications

Small Molecule Approaches

Targeting TUFM-related pathways [12]:

• Mitochondrial translation inhibitors (gentamicin, chloramphenicol)
• OXPHOS enhancers
• Antioxidants
• Metabolic modulators

Gene Therapy

Emerging approaches:

• AAV-mediated TUFM delivery
• CRISPR-based gene editing
• mRNA delivery for protein expression

Biomarker Potential

TUFM as a biomarker:

• Blood TUFM levels in mitochondrial disease
• CSF TUFM in neurodegeneration
• Muscle biopsy for diagnosis

Animal Models

Mouse Models

• Tufm conditional knockout: Brain-specific deletion
• Tufm heterozygous: Partial loss of function
• Transgenic expression: Disease variants

Zebrafish Models

Zebrafish models of TUFM deficiency [13]:

• Morpholino knockdown
• CRISPR mutants
• Phenotype: developmental arrest, mitochondrial dysfunction

Drosophila Models

Fruit fly models [14]:

• TUFM knockdown
• Mutant phenotypes
• Genetic modifiers identified

Research Methods

Biochemical Techniques

• Mitochondrial translation assays
• GTPase activity measurements
• OXPHOS enzyme activities
• Blue-native PAGE

Genetic Approaches

• Whole exome sequencing
• Variant interpretation
• Genotype-phenotype correlation
• Population genetics

Imaging

• Mitochondrial morphology (confocal microscopy)
• Mitochondrial membrane potential
• ROS imaging

Population Genetics

Variant Frequencies

• Common variants: Generally benign
• Rare missense: Variable pathogenicity
• Loss-of-function: Usually pathogenic

Founder Mutations

• Certain populations have TUFM founder mutations
• Recessive inheritance pattern
• Carrier frequency varies by ancestry

Clinical Testing

Diagnostic Approach

Treatment Options

Current management strategies:

• Supportive care: Multidisciplinary approach
• Seizure control: Antiepileptic medications
• Cardiac management: Beta-blockers, pacing if needed
• Physical therapy: Maintain function
• Dietary modifications: Ketogenic diet may help some patients
• CoQ10 supplementation: Sometimes beneficial
• L-arginine: For MELAS features

Prognosis

Prognosis varies by genotype and phenotype:

• Severe TUFM mutations: Often fatal in childhood
• Mild variants: May survive to adulthood with disability
• Cardiomyopathy: Often determines outcome
• Early intervention improves quality of life

Structure-Function Relationships

GTPase Domains

The GTPase domains of TUFM are critical:

• GTP binding: Essential for function
• GTP hydrolysis: Regulated by ribosome
• GDP dissociation: Requires TSFM cofactor

tRNA Interaction

The tRNA-binding surface:

• Recognizes all mitochondrial tRNAs
• Requires proper aminoacylation
• Affected by disease variants

Ribosome Binding

Ribosome interaction sites:

• A-site binding
• GTPase stimulation
• Translocation

Mitochondrial Quality Control

Translation Fidelity

TUFM ensures translation accuracy:

• Correct codon-anticodon pairing
• Proofreading mechanisms
• Misfolded protein degradation

Ribosome Quality Control

Mitochondrial ribosome quality control:

• Stalled ribosome rescue
• Non-stop decay
• Ribosome recycling

Protein Folding

Post-translational handling:

• Mitochondrial chaperones
• OXPHOS assembly factors
• Degradation pathways

Evolutionary Perspective

Conservation

TUFM is highly conserved:

• Bacterial EF-Tu: ~50% identity
• Mammalian TUFM: >90% identity
• Essential for viability

Mitochondrial Origins

Evolutionary history:

• Derived from alpha-proteobacteria
• Retained bacterial-like translation
• Essential for organelle function

Gene Family

No close paralogs in humans; TUFM is unique.

Metabolism and Energy

Cellular Energy Balance

TUFM affects cellular energetics:

• ATP production capacity
• Metabolic flexibility
• Redox balance

Stress Response

TUFM in cellular stress:

• Oxidative stress response
• Nutrient sensing
• Apoptosis regulation

Research Challenges

Model Systems

Challenges in studying TUFM:

• Mitochondrial complexity
• Tissue-specific effects
• Developmental timing

Therapeutic Development

Barriers to therapy:

• Delivery to mitochondria
• Protein folding issues
• Off-target effects

Future Directions

Unresolved Questions

Key research priorities:

• Why specific tissues affected?
• Can we enhance residual function?
• What determines phenotype severity?

Emerging Approaches

Future therapies may include:

• Mitochondria-targeted small molecules
• Gene therapy vectors
• Protein replacement
• Modulation of mitochondrial dynamics

Summary

TUFM is essential for mitochondrial protein synthesis and oxidative phosphorylation. As the mitochondrial translation elongation factor, it delivers aminoacyl-tRNAs to the mitochondrial ribosome, enabling synthesis of the 13 mtDNA-encoded OXPHOS subunits. TUFM mutations cause severe mitochondrial diseases including encephalomyopathy, Leigh syndrome, and cardiomyopathy, highlighting its critical role in energy metabolism. Emerging evidence also links TUFM to common neurodegenerative diseases such as [Parkinson's](/diseases/parkinsons-disease) and [Alzheimer's](/diseases/alzheimers-disease), where mitochondrial dysfunction plays a key role. Understanding TUFM function and developing therapies for TUFM-related conditions represents an important frontier in mitochondrial medicine and neurodegeneration research.

Mitochondrial Translation in Detail

The Mitochondrial Ribosome

The mitochondrial ribosome (55S in mammals) is distinct from cytosolic ribosomes:

• Contains 28S small subunit and 39S large subunit
• Contains 2 rRNA molecules (12S and 16S in humans)
• Proteins distinct from bacterial ribosomes
• Specialized for membrane protein synthesis

tRNA Selection

TUFM must discriminate among mitochondrial tRNAs:

• 22 tRNAs encoded in mtDNA
• Modified bases affect recognition
• Certain tRNAs have unique features

Translation Rates

Mitochondrial translation is slower than bacterial:

• Average elongation rate: ~2 amino acids/second
• Quality control at each step
• Coordination with OXPHOS assembly

TUFM and Cellular Stress

Oxidative Stress Response

TUFM is affected by oxidative stress:

• Oxidation of critical cysteine residues
• Aggregation under stress
• Enhanced degradation

Metabolic Stress

In metabolic stress:

• AMP/ATP ratio affects translation
• Nutrient deprivation reduces translation
• Stress signaling modulates TUFM

Endoplasmic Reticulum Stress

Cross-talk between compartments:

• Mitochondrial dysfunction triggers UPR
• Translation coordinated across compartments
• Apoptotic signals intersect

Clinical Management

Neonatal Screening

Potential for newborn screening:

• Elevated lactate flag
• Genetic testing confirmation
• Early intervention benefits

Prenatal Diagnosis

For families with known TUFM variants:

• Chorionic villus sampling (10-14 weeks)
• Amniocentesis (15-18 weeks)
• Preimplantation genetic diagnosis

Adult Carriers

For carriers of recessive variants:

• Generally asymptomatic
• Possible manifestations under stress
• Genetic counseling important

Pharmacological Approaches

Current Treatments

Existing therapies:

• L-arginine: May improve energy status
• CoQ10: Electron carrier supplementation
• Riboflavin: Complex I deficiency support
• Ketogenic diet: Alternative energy source

Emerging Compounds

Drug development targets:

• Mitochondria-penetrating antioxidants
• Translation modulators
• OXPHOS assembly enhancers

Nutritional Interventions

Dietary considerations:

• High-calorie diets for能耗 demands
• Fat adaptation for ketones
• Avoidance of fasting

Research Techniques

Proteomics

Studying TUFM in context:

• Mitochondrial proteomics
• Interaction mapping
• Post-translational modifications

Genomics

Understanding variants:

• Variant calling from sequencing
• Pathogenicity prediction
• Population allele frequencies

Metabolomics

Metabolic consequences:

• Lactic acid elevation
• Amino acid profiles
• Energy metabolites

TUFM in Different Cell Types

Neurons

Special considerations in neurons:

• High energy demands
• Non-dividing cells
• Mitochondrial inheritance

Cardiomyocytes

Cardiac-specific effects:

• Constant contractile work
• High OXPHOS dependence
• Limited regenerative capacity

Muscle Cells

Skeletal muscle features:

• Exercise-responsive
• Mitochondrial density high
• Fatigue sensitivity

Environmental Interactions

Toxins

Environmental toxins affecting TUFM:

• Rotenone: Complex I inhibitor
• Antimycin A: Complex III inhibitor
• Oligomycin: Complex V inhibitor

Drugs

Drug effects on TUFM:

• Chloramphenicol: Direct inhibitor
• Aminoglycosides: Affect translation
• Some chemotherapeutics

Comparative Biology

Model Organisms

Studying TUFM across species:

• Yeast: Mitochondrial translation
• Drosophila: In vivo studies
• Zebrafish: Developmental models
• Mouse: Mammalian physiology

Species Differences

Evolutionary variations:

• Different tRNA requirements
• Tissue-specific regulation
• Disease phenotypes vary

Future Perspectives

The study of TUFM continues to evolve:

See Also

• [Mitochondrial Translation](/mechanisms/mitochondrial-translation)
• [OXPHOS Complexes](/mechanisms/oxidative-phosphorylation)
• [Leigh Syndrome](/diseases/leigh-syndrome)
• [Mitochondrial Encephalomyopathy](/diseases/mitochondrial-encephalomyopathy)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics)

External Links

• [NCBI Gene: TUFM](https://www.ncbi.nlm.nih.gov/gene/7284)
• [UniProt: TUFM](https://www.uniprot.org/uniprot/P49411)
• [OMIM: TUFM](https://www.omim.org/entry/609377)
• [MITOMAP: TUFM](https://www.mitomap.org/)

References

Pathway Diagram

Key molecular relationships involving tufm from the SciDEX knowledge graph:

Pathway Diagram

The following diagram shows the key molecular relationships involving TUFM Gene discovered through SciDEX knowledge graph analysis: